North Carolina is currently home to 2670 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
NCT05739955
Recruiting
The purpose of this study is to determine if enhanced daily application of disinfectant with persistent 24-hour activity decreases the environmental bioburden compared to standard practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Duke University, Durham, North Carolina
Conditions: Disinfection
Register for Updates
Altitudes for Caregivers
NCT06094647
Recruiting
The objective of this study is to assess the acceptability and feasibility of Altitudes, a novel digital behavioral health and psychoeducational intervention for caregivers and supporters of individuals experiencing first episode psychosis. The investigators will evaluate acceptability and feasibility with up to 30 caregivers and supporters over the course of 6 months. Acceptability and usability will be assessed with various acceptability measures with the Altitudes caregivers and supporters, c... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/29/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Care Burden, Care Giving Burden, Caregiver Burnout, Caregiver Stress, Caregiver Wellbeing, Support, Family
Register for Updates
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
NCT05638581
Recruiting
The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.
Gender:
All
Ages:
15 years and above
Trial Updated:
02/29/2024
Locations: Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
Conditions: Wounds and Injuries, Shock, Hemorrhagic
Register for Updates
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
NCT05130866
Recruiting
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
Gender:
All
Ages:
12 years and above
Trial Updated:
02/29/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Neurofibromatosis Type 2
Register for Updates
Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
NCT02633163
Recruiting
The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/29/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Systemic Lupus Erythematosus
Register for Updates
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05434689
Recruiting
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administrat... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
02/28/2024
Locations: Duke University, Durham, North Carolina
Conditions: Multiple Myeloma
Register for Updates
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
NCT05076760
Recruiting
This phase I trial is designed in two parts. First as an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) who have a tumor lesion which is accessible for injection will undergo intratumoral injection of MEM-288. Following completion of the monotherapy study portion of the study, an expansion arm is desig... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Register for Updates
A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam
NCT05067790
Recruiting
The primary objective of this study is to evaluate motor function following treatment with HD nusinersen in participants with spinal muscular atrophy (SMA) previously treated with risdiplam. The secondary objective of this study is to evaluate the safety and tolerability of HD nusinersen in participants with SMA previously treated with risdiplam.
Gender:
All
Ages:
Between 15 years and 50 years
Trial Updated:
02/28/2024
Locations: Wake Forest University - School of Medicine - Central, Winston-Salem, North Carolina
Conditions: Spinal Muscular Atrophy
Register for Updates
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
NCT03500328
Recruiting
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Ear... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: Novant Health Neurology and Sleep, Charlotte, North Carolina
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Dissemination and Implementation of Improving Pediatric Obesity Practice Using Prompts
NCT05627011
Recruiting
The purpose of this study is to evaluate the dissemination and implementation of electronic health record-based clinical decision support tools for the management of pediatric overweight and obesity in primary care.
Gender:
All
Ages:
2 years and above
Trial Updated:
02/27/2024
Locations: Duke University, Durham, North Carolina
Conditions: Obesity, Childhood
Register for Updates
Virtual Reality Visual Field Testing as an Alternative in Childhood Eye Disease
NCT05150197
Recruiting
The purpose of this study is to test a new way of measuring the peripheral vision (called a visual field test) using a device which can be worn as goggles rather than being a large instrument the patient must sit at. This new visual field test (called VisuALL) is an FDA-approved virtual reality system which has been used in adults and children. This study will compare the performance of the VisuALL to the standard testing for peripheral vision, which is called the Humphrey Visual Field (HVF) tes... Read More
Gender:
All
Ages:
Between 4 years and 21 years
Trial Updated:
02/27/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Visual Field Defect, Peripheral
Register for Updates
Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support
NCT04309565
Recruiting
TCN PATHS will recruit an anticipated 400 participants who are prescribed MOUD who are released from detention facilities. Each individual will be randomized to either 1) standard primary care (SPC) or 2) a Transitions Clinic Network (TCN) program primary care. Participants will be followed for a year and complete surveys at baseline and at month 1, 3, 6, 9, and 12. At each of these points research staff will confirm MOUD status. Urine drug screenings will be completed at baseline, month 1, 6, a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: UNC Chapel Hill, Chapel Hill, North Carolina
Conditions: Opioid Addiction
Register for Updates